Local inhibition of tyrosine kinase activity markedly attenuates the development of intimal hyperplasia in experimental vein grafts

Journal of Surgical Research

Volumn 77, Issue 2, 1998, Pages 104-111

  Huynh, Tam T T ^a   Davies, Mark G ^a   Barber, Lizzie ^a   Svendsen, Einar ^b   Hagen, Per Otto ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Dimethyl sulfoxide; Intimal hyperplasia; Rabbit; Tyrosine kinase; Vein graft

Indexed keywords

PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; RABBIT; VEIN GRAFT;

EID: 0032123342     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1998.5300     Document Type: Article

References (37)

1. Sayers R., Jones L., Varty K. The histopathology of infrainguinal vein graft stenoses. Eur. J .Vasc. Surg. 7:1993;16.
2. Davies M. G., Dalen H., Kim J. H., Barber L., Svendsen E., Hagen P.-O. Control of accelerated vein graft atheroma with the nitric oxide precursor:L. J. Surg. Res. 59:1995;35.
3. Davies M. G., Hagen P.-O. Pathophysiology of vein graft failure: a review. Eur. J. Vasc. Endovasc. Surg. 9:1995;7.
4. Davies M. G., Hagen P.-O. Pathobiology of intimal hyperplasia. Br. J. Surg. 81:1994;1254.
5. Hoch J. R., Stark V. K., Hulett D. A., Turnipseed W. D. Vein graft intimal hyperplasia: Leucocytes and cytokine gene expression. Surgery. 116:1994;463.
6. Hoch J. R., Stark V. K., Turnipseed W. D. The temporal relationship between the development of vein graft intimal hyperplasia and growth factor gene expression. J. Vasc. Surg. 22:1995;51.
7. Newby A. C., George S. J. Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies. Cardiovasc. Res. 27:1993;1173.
8. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203.
9. van Biesen T., Luttrell L. M., Hawes B. E., Lefkowitz R. J. Mitogenic signaling via G-protein-coupled receptors. Endocr. Rev. 17:1996;698.
10. Shimokado K., Yokota T., Umezawa K., Sasaguri T., Ogata J. Protein tyrosine kinase inhibitors inhibit chemotaxis of vascular smooth muscle cells. Arterioscler. Thromb. 14:1994;973.
11. Bilder G. E., Krawiec J. K., McVety K., Gazit A., Gilon C., Lyall R., Zilberstein A., Levitski A., Perrone M. H., Schreiber A. B. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am. J. Physiol. 260:1991;C721.
12. Golomb G., Fishbein I., Banai S., Mishaly D., Moscovitz D., Gertz S. D., Gazit A., Poradosu E., Levitzki A. Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. Atherosclerosis. 125:1996;171.
13. Davies M. G., Barber L., Dalen H., Svendsen E., Hagen P-O. Control of the structural and functional consequences of vein graft intimal hyperplasia by a 21-aminosteroid (U74389G). Eur. J. Vasc. Surg. 8:1994;448.
14. Fulton G. J., Davies M. G., Koch W. J., Dalen H., Svendsen E., Hagen P-O. Antisense oligonucleotide to proto-oncogenec-myb. J. Vasc. Surg. 25:1997;453.
15. Finney D. J. Quantal responses and the tolerance distribution. Statistical Methods in Biological Assay. 1978;Charles Griffin, London. p. 349-369.
16. Davies M. G., Hagen P-O. Pathophysiology of vein graft failure. Eur. J. Vasc. Surg. 8:1995;7.
17. Rosengurt E. Signal transduction pathways in mitogenesis. Br. Med. Bull. 45:1989;515.
18. Ferns G. A., Raines E. W., Sprugel K. H., Motani A. S., Reidy M. A., Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 253:1991;1129.
19. Lindner V., Reidy M. A. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA. 88:1991;3739.
20. Levitzki A. Tyrphostins: Tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J. 6:1992;3275.
21. Sharfe N., Dadi H. K., Roifman C. M. JAK3 protein tyrosine kinase mediates interleukin-7-induced activation of phosphatidylinositol-3 kinase. Blood. 86:1995;2077.
22. Linseman D. A., Benjamin C. W., Jones D. A. Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J. Biol. Chem. 270:1995;12563.
23. Kozai T., Shimokawa H., Fukumoto Y., Kobayashi S. Tyrosine kinase inhibitor markedly suppresses the development of coronary lesions induced by long-term treatment withJ J. J. Cardiovasc. Pharmacol. 29:1997;536.
24. Gottsauner-Wolf M., Jang Y., Lincoff M., Cohen J., Labhasetwar V. Influence of local delivery of the protein kinase receptor inhibitor tyrphostin-47 on smooth muscle cell proliferation in a rat carotid balloon-injury model. Am. Heart J. 133:1997;329.
25. Kohler T. R., Kirkman T. R., Clowes A. W. The effect of rigid external support on vein graft adaptation to the arterial circulation. J. Vasc. Surg. 9:1989;277.
26. Ohara Y., Petersen T., Harrison D. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91:1993;2546.
27. Mugge A., Elwell J., Peterson T., Hofmeyer T. Chronic treatment with polyethylene-glycolated superoxide partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ. Res. 69:1991;1293.
28. Davies M. G., Dalen H., Barber L., Svendsen E., Hagen P-O. Lazaroid therapy (methylaminochroman: U83836E) reduces vein graft intimal hyperplasia. J. Surg. Res. 63:1996;128.
29. Hagen P.-O., Davies M. G., Schuman R. W., Murray J. J. Reduction of vein graft intimal area by ex-vivo treatment with desferroxamine manganese. J. Vasc. Res. 29:1992;405.
30. Ankers D. L., Aurora H. S., Bedi B., Santiago K., Canales K., Kadowitz R. J., McNamera D. B. Effect of 21-aminosteroid antioxidant U74389F on development of intimal hyperplasia following balloon catheter injury in rabbit thoracic aorta (abstract). FASEB J. 7:1993;A339.
31. Xiao J., Biaglow J., Chae-Park H.-J., Jin J. Role of hydroxyl radicals in radiation-induced activation of Lyn tyrosine kinase in human B-cell precursors. Leukemia Lymphoma. 22:1996;421.
32. O Donohoe M., Schwartz L. B., Radic Z. S., Mikat E. M., McCann R. L., Hagen P-O. Chronic ACE inhibition reduces intimal hyperplasia in experimental vein grafts. Ann. Surg. 214:1991;727.
33. Davies M. G., Barber L., Dalen H., Svendsen E., Hagen P-O. Control of the structural and functional consequences of vein graft intimal hyperplasia with a 21-aminosteroid-U74389G. Eur. J. Vasc. Surg. 8:1994;448.
34. Levitzki A. Tyrphostins - Potential antiproliferative agents and novel molecular tools. Biochem. Pharmacol. 40:1990;913.
35. Davies M., Fulton G., Barber L., Dalen H., Hagen P-O. Characterisation of angiotensin II receptor mediated responses and inhibition of intimal hyperplasia in experimental vein grafts by the specific angiotensin II receptor inhibitor, L158,809. Eur. J. Vasc. Endovasc. Surg. 12:1996;151.
36. Schwartz L. B., Haines L. J., Massey M. F., Kerfoot W. W., McCann R. L., Hagen P-O. Dependence of rabbit external jugular vein vasoreactivity on segment size and location. Vasc. Surg. 28:1994;15.
37. Davies M. G., Ramkumar V., M. L. K., Hagen P-O. The expression and function of G-proteins in experimental vein grafts. J. Clin. Invest. 94:1994;1680.